caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and tangier disease. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Cholesterol translocation",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and aging. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, aging, and tangier disease. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, diabetes mellitus type 2, and alzheimer's disease. | CC/C=C\C/C=C\CC(O)/C=C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCc1oc(CCCCC)c(C)c1C | [
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"nutrient",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, aging, and barth syndrome. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts tangier disease and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC[C@@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts aging. The molecule is a stabilizing mitochondrial structure that impacts tangier disease, non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCOC(=O)CC1CCC(=O)C1C/C=C/CCOC1OC(CO)C(O)C(O)C1O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the proliferative disease treatment class of molecules. | N=C(ONC(=O)c1ccccc1)ONC(=O)c1ccccc1 | [
"proliferative disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, nutrient, fat storage that impacts pancreatitis, obesity, and cancer. The molecule is a energy source that impacts both metabolic syndrome and atherosclerosis. The molecule is a thyroxine treatment, a membrane stabilizer, and a energy storage, and it impacts cardiovascular disease. | CCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCC | [
"Pancreatitis",
"inflammatory",
"nutrient",
"Obesity",
"Fat storage",
"Cancer",
"Energy source",
"Metabolic syndrome",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment",
"Membrane stabilizer",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a differentiator, a anti dysmenorrheic, and a anti thrombophlebitic, belonging to the anti inflammatory class of molecules and is fibrinolytic. The molecule is a lipolytic and a laxative, belonging to the anti tumor, anti cellulitic, and anti edemic classes of molecules, and is anti proliferant. The mol... | CC(OP(=O)(O)O)C(N=C(O)CCCCCCS)C(=O)O | [
"differentiator",
"anti dysmenorrheic",
"anti thrombophlebitic",
"anti inflammatory",
"fibrinolytic",
"anti proliferant",
"anti tumor",
"anti cellulitic",
"anti edemic",
"lipolytic",
"laxative",
"anti appetant",
"proliferant",
"analgesic",
"vulnerary",
"anti radiation",
"anti neoplas... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, aging, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and aging. | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, barth syndrome, and tangier disease. The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the organic light-emitting device class of molecules. | c1ccc(-c2c(-c3ccccc3)n(-c3ccc4ccccc4c3)c3cc4ccc5cc(-c6cccc(-c7ccncc7)n6)ccc5c4cc23)cc1 | [
"organic light-emitting device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pesticide, a ec 1.14.18.1 (tyrosinase) inhibitor, woody, nutty, and almond. The molecule is a allelochemic that is pharmaceutical, balsam, and sweet, and it impacts cancer preventive. | COc1cc(CC(=O)C(=O)O)ccc1O | [
"woody",
"nutty",
"almond",
"pesticide",
"EC 1.14.18.1 (tyrosinase) inhibitor",
"cancer preventive",
"Pharmaceutical",
"balsam",
"allelochemic",
"sweet"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts seizure, cardiovascular disease, and colorectal cancer. It has an effect on breast cancer, and impacts parkinson's disease, diabetes mellitus, and alzheimer's disease. | CCCCC/C=C\C/C=C\CC(O)/C=C\C=C\CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCCCC/C=C\CCCCCC | [
"Stomach cancer",
"Seizure",
"Cardiovascular disease",
"Colorectal cancer",
"Breast cancer",
"Parkinson's disease",
"Diabetes mellitus",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, aging, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Apoptosis",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts aging, tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti oxidant class of molecules. | CCCCSC(CCC)OC(=O)CCc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1 | [
"anti oxidant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a light-emitting member of the optoelectronic class. | N#Cc1ccc(-c2c(-n3c4ccccc4c4ccc(-n5c6ccccc6c6ccccc65)cc43)cncc2-n2c3ccccc3c3ccc(-n4c5ccccc5c5ccccc54)cc32)cc1 | [
"light-emitting",
"optoelectronic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts aging and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts atherosclerosis, ulcerative colitis, breast cancer, and cervical cancer. | CCCCC/C=C\C=C/[C@H](O)C/C=C\C/C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"Atherosclerosis",
"Ulcerative colitis",
"Breast cancer",
"nutrient",
"Cervical cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and pancreatitis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that affects cancer by impacting cardiovascular disease, pancreatitis, obesity, and metabolic syndrome. The molecule is a energy storage, a fat storage, and a thyroxine treatment. The molecule is a inflammatory, a membrane stabilizer, and a nutrient, and it impacts atherosclerosis. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Energy source",
"Cancer",
"Cardiovascular disease",
"Pancreatitis",
"Obesity",
"Metabolic syndrome",
"Energy storage",
"Fat storage",
"Thyroxine treatment",
"Atherosclerosis",
"inflammatory",
"Membrane stabilizer",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a egfr inhibitor. | COc1cc2c(cc1Nc1ncc(Br)c(Nc3ccc4nccnc4c3P(C)(C)=O)n1)OCCN2CCN(C)C | [
"egfr inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCC[C@@H](C)O)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to both the electroluminescent and organic electroluminescent device classes of molecules. | CC(C)(C)C12CCC(O1)c1cccc(F)c12 | [
"electroluminescent",
"organic electroluminescent device"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti inflammatory class of molecules. | COC(=O)C=CC(=O)OCC(COC(=O)C=CC(=O)OC)OC(=O)CCC(=O)OCCOCCOCCOCCOC(=O)Cc1c(-c2ccc(Cl)cc2)c(-c2ccccc2)c2n1CC(C)(C)C2 | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the electroluminescent class of molecules. | CC(C)(C)n1c2ccccc2c2cc(-c3cccc(N)c3)ccc21 | [
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, a membrane stabilizer, and a nutritional supplement, and it impacts non-alcoholic fatty liver disease. The molecule is a emulsifier, energy storage, stabilizing cytochrome oxidase, surfactant that impacts aging. The molecule is a proton trap for oxidative phosphorylation and... | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"Nutritional supplement",
"Emulsifier",
"Energy storage",
"Stabilizing cytochrome oxidase",
"surfactant",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"food additive",
"Diabet... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy storage, energy source, nutrient, thyroxine treatment that impacts metabolic syndrome. The molecule is a inflammatory that impacts both pancreatitis and atherosclerosis. The molecule is a fat storage that affects cancer by impacting both obesity and cardiovascular disease. | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCC | [
"Membrane stabilizer",
"Metabolic syndrome",
"Energy storage",
"Energy source",
"nutrient",
"Thyroxine treatment",
"Pancreatitis",
"inflammatory",
"Atherosclerosis",
"Cancer",
"Obesity",
"Fat storage",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Aging",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and atherosclerosis. The molecule is a fat storage and thyroxine treatment, impacting both pancreatitis and metabolic syndrome. | CCCC/C=C\CCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Fat storage",
"Metabolic syndrome",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on colorectal cancer, and impacts seizure, diabetes mellitus, and parkinson's disease. It has an effect on breast cancer, and impacts stomach cancer, cardiovascular disease, and alzheimer's disease. | CCCCCCCC/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCC(O)/C=C/C=C/C/C=C/CCCCCCCC | [
"Seizure",
"Diabetes mellitus",
"Parkinson's disease",
"Colorectal cancer",
"Stomach cancer",
"Breast cancer",
"Cardiovascular disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis that impacts aging, diabetic heart disease, tangier disease, and barth syndrome. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC | [
"Aging",
"Diabetic heart disease",
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The fluorescent molecule has an effect on photoresist. | CCCC(C(=O)Nc1ccc(OCC2CO2)cc1)N1C(=O)c2cc(Oc3ccc(C(C)(C)C)cc3)c3c4c(Oc5ccc(C(C)(C)C)cc5)cc5c6c(cc(Oc7ccc(C(C)(C)C)cc7)c(c7c(Oc8ccc(C(C)(C)C)cc8)cc(c2c37)C1=O)c64)C(=O)N(C(CCC)C(=O)Nc1ccc(OCC2CO2)cc1)C5=O | [
"fluorescent",
"photoresist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to both the anti obesity and npy y5 antagonist classes of molecules. | C=C(CCCC(C)N)C(O)NC(C)C | [
"anti obesity",
"npy y5 antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | COc1ccc(-c2cc(=O)c3c(O)cc(OC4OC(CO)C(O)C(O)C4O)cc3o2)cc1O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti cancer. | COc1cc(OC)c(F)c(N(CCNC2COC2)C2=NC3N=C(c4cnn(C)c4)C=NC3C=C2)c1F | [
"anti cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a organic electroluminescent device and belongs to the electroluminescent class of molecules, known to have an effect on improved luminous efficiency. | Clc1ccc(-c2nc(-c3ccc(Cl)cc3)nc(-n3c4ccccc4c4ccc5cc6c7ccccc7c7ccccc7n6c5c43)n2)cc1 | [
"organic electroluminescent device",
"improved luminous efficiency",
"electroluminescent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the ppar agonist class of molecules. | O=C(O)C1CCCC(CO)C1 | [
"ppar agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, nutrient, emulsifier, surfactant, energy storage, membrane stabilizer. | CC1(C)CCC2(CO)C(=C3CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CC2O)C1 | [
"Energy source",
"nutrient",
"Emulsifier",
"surfactant",
"Energy storage",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, alzheimer's disease, parkinson's disease, and non-alcoholic fatty liver disease. | CCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCC(O)/C=C/C=C/C/C=C/CCCCCCCC | [
"Diabetes mellitus type 2",
"Alzheimer's Disease",
"Parkinson's disease",
"nutrient",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, energy source, emulsifier, energy storage. The molecule is a membrane stabilizer, signalling molecule, surfactant, hormone that impacts metabolic syndrome. | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3C(O)CC4CC(O)CC[C@]4(C)[C@H]3CC(O)[C@]12C | [
"inflammatory",
"Energy source",
"Emulsifier",
"Energy storage",
"Membrane stabilizer",
"signalling molecule",
"surfactant",
"Metabolic syndrome",
"hormone"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pde1 inhibitor. | C#CCN(Cc1ccc(OC)cc1)C(=O)c1c(C)oc2ncnc(NC3(C)CC3)c12 | [
"pde1 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a factor xia inhibitor and a kinase inhibitor, as well as cancer treatment and alzheimer's disease treatment. | NC(=O)CCCC1CCCO1 | [
"cancer treatment",
"factor xia inhibitor",
"alzheimer's disease treatment",
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCC1OC1C/C=C\CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of both the cancer treatment and anti inflammatory classes and affects hyperproliferative disorder treatment, while also being characterized as anti cancer. | O=C(NOCCO)c1cc(F)c2nncn2c1Nc1ccc(I)cc1F | [
"hyperproliferative disorder treatment",
"cancer treatment",
"anti cancer",
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts aging and tangier disease. | CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, non-alcoholic fatty liver disease, parkinson's disease, and alzheimer's disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Diabetes mellitus type 2",
"nutrient",
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a energy storage, impacting both aging and barth syndrome. The molecule is a surfactant and a apoptosis, which impacts both non-alcoholic fatty liver disease and diabetic heart disease, and is characterized as smooth. The molecule is a membrane stabilizer, stabilizing mit... | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Aging",
"Cholesterol translocation",
"Energy storage",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"surfactant",
"Apoptosis",
"Smooth",
"Diabetic heart disease",
"Membrane stabilizer",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Stabilizin... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts cardiovascular disease, seizure, and alzheimer's disease. It has an effect on colorectal cancer, and impacts diabetes mellitus, breast cancer, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCC[C@@H](O)[C@H](O)/C=C\C=C/C=C/C=C/[C@@H](O)C/C=C\CC | [
"Cardiovascular disease",
"Seizure",
"Stomach cancer",
"Alzheimer's Disease",
"Diabetes mellitus",
"Breast cancer",
"Colorectal cancer",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti apoptotic class of molecules. | CN(C)CC1COC(COc2ccc(Cl)cc2)C1.Cl | [
"anti apoptotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti inflammatory and hyperglycemia treatment. | CCCOc1c(OCCCOc2cccc(CC(OC(C)C)C(=O)O)c2)ccc(C(C)=O)c1O | [
"anti inflammatory",
"hyperglycemia treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and a surfactant, as well as aldehydic and fruity. The molecule is a energy source, emulsifier, nutrient, energy storage, and citrus. | CC(C)CCCC(C)CC=O | [
"aldehydic",
"fruity",
"Membrane stabilizer",
"surfactant",
"Energy source",
"Emulsifier",
"nutrient",
"Energy storage",
"citrus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, thyroxine treatment, energy storage that impacts obesity, metabolic syndrome, and pancreatitis. The molecule is a membrane stabilizer and fat storage, and it impacts cardiovascular disease. The molecule is a inflammatory and a energy source, impacting both atherosclerosis and cancer. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC(C)C | [
"nutrient",
"Obesity",
"Metabolic syndrome",
"Thyroxine treatment",
"Pancreatitis",
"Energy storage",
"Membrane stabilizer",
"Fat storage",
"Cardiovascular disease",
"inflammatory",
"Atherosclerosis",
"Energy source",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, emulsifier, stabilizing mitochondrial structure, energy source. The molecule is a stabilizing cytochrome oxidase, energy storage, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a membrane stabilizer and a ... | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Emulsifier",
"Stabilizing mitochondrial structure",
"Energy source",
"Stabilizing cytochrome oxidase",
"Energy storage",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Membrane stabilizer",
"surfactant",
"Tangier disea... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ec 3.1.1.7 (acetylcholinesterase) inhibitor and belongs to the agrochemical class of molecules; it is avicide and acaricide. | O=c1nc(O)n(Cl)c(=O)n1Cl | [
"EC 3.1.1.7 (acetylcholinesterase) inhibitor",
"avicide",
"agrochemical",
"acaricide"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts alzheimer's disease, non-alcoholic fatty liver disease, diabetes mellitus type 2, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C[C@@H](O)[C@H](O)CCCC(=O)O[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OCCN | [
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"nutrient",
"Diabetes mellitus type 2",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti bacterial class of molecules. | COc1cc(Cl)c(Sc2ccccc2C=O)c(CNC(O)OCC2c3ccccc3-c3ccccc32)c1 | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and a nutrient that impacts thyroxine treatment, obesity, atherosclerosis, and cardiovascular disease. The molecule is a energy storage that impacts both pancreatitis and metabolic syndrome. The molecule is a inflammatory, a energy source, and a membrane stabilizer, and it impacts cancer. | CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)CC | [
"Thyroxine treatment",
"Obesity",
"Fat storage",
"Atherosclerosis",
"Cardiovascular disease",
"nutrient",
"Pancreatitis",
"Energy storage",
"Metabolic syndrome",
"Cancer",
"inflammatory",
"Energy source",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a surfactant, energy source, emulsifier, membrane stabilizer, energy storage, nutrient. | [O][O-] | [
"surfactant",
"Energy source",
"Emulsifier",
"Membrane stabilizer",
"Energy storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | CCS(=O)(=O)Nc1ccc(-c2cn(CCO)nc2-c2ccncc2)cc1 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, a energy source, and a proton trap for oxidative phosphorylation, and it impacts aging. The molecule is a energy storage, a stabilizing mitochondrial structure, and a surfactant, it impacts non-alcoholic fatty liver disease and is smooth. The molecule is a stabilizing cytochrom... | CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Nutritional supplement",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Aging",
"Energy storage",
"Non-alcoholic fatty liver disease",
"Smooth",
"Stabilizing mitochondrial structure",
"surfactant",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, inflammatory, nutrient that impacts cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a membrane stabilizer and energy storage, and it impacts cancer. The molecule is a thyroxine treatment and a energy source, impacting both atherosclerosis and obesity. | CCC(C)CCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Cardiovascular disease",
"Fat storage",
"Pancreatitis",
"inflammatory",
"nutrient",
"Metabolic syndrome",
"Membrane stabilizer",
"Cancer",
"Energy storage",
"Atherosclerosis",
"Thyroxine treatment",
"Obesity",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti inflammatory. | COC1=C(OC)C(=O)C(Cc2ccc(O)c(C(=O)Nc3ccncc3)c2)=C(C)C1=O | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts aging and tangier disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti tussive class of molecules. | CC(=O)CNc1ccc(C(=O)OC(C)(C)C)cc1 | [
"anti tussive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and metabolic syndrome. The molecule is a nutrient and thyroxine treatment, impacting both atherosclerosis and pancreatitis. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"Cardiovascular disease",
"Metabolic syndrome",
"Fat storage",
"Atherosclerosis",
"nutrient",
"Thyroxine treatment",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both metabolic syndrome and cardiovascular disease. The molecule is a fat storage and a nutrient, impacting both pancreatitis and atherosclerosis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@@H](COC(=O)CCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Thyroxine treatment",
"Metabolic syndrome",
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"nutrient",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti proliferative that impacts cancer treatment. | C=CCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC | [
"cancer treatment",
"anti proliferative"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts tangier disease and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Tangier disease",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a glycosidase inhibitor. | CCCN(C)C1=NC2CCC(C(C)O)OC2S1 | [
"glycosidase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is psychiatric treatment. | CCn1c(C2CCCN(C(=O)c3cnnc(NC)c3)C2)c(C)c2ccccc21 | [
"psychiatric treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both atherosclerosis and pancreatitis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both cardiovascular disease and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Atherosclerosis",
"Pancreatitis",
"nutrient",
"Cardiovascular disease",
"Fat storage",
"Thyroxine treatment",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and energy source, belonging to the thyroxine treatment class of molecules, and impacts pancreatitis, obesity, and cardiovascular disease. The molecule is a energy storage and membrane stabilizer, and it impacts metabolic syndrome. The molecule is a inflammatory and a fat storage, impacting b... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Pancreatitis",
"Obesity",
"nutrient",
"Thyroxine treatment",
"Cardiovascular disease",
"Energy source",
"Energy storage",
"Membrane stabilizer",
"Metabolic syndrome",
"Atherosclerosis",
"inflammatory",
"Cancer",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts tangier disease and diabetic heart disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts tangier disease, barth syndrome, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti tumor. | CCc1cc2c(cc1N1CCC(N3CCN(C(=O)COc4ccc5c(c4)CN(C4CCC(=O)NC4=O)C5=O)CC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O | [
"anti tumor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, a signalling molecule, and a nutrient. The molecule is a surfactant, membrane stabilizer, energy source, energy storage. | CC1CC2OC3C(CC2OC2CC4OC5C/C=C\CC6OC7C=CC8OC9C(CC8OC7C=CC6OC5CC(O)C4(C)OC2C1)OC1CC(O)CC(/C=C\C(O)CO)OC1C9O)OC1C(C)C(C)C2(CC(O)CO2)OC1C(O)C3C | [
"Emulsifier",
"signalling molecule",
"nutrient",
"surfactant",
"Membrane stabilizer",
"Energy source",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, tangier disease, and diabetic heart disease. | CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging",
"Tangier disease",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Apoptosis",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts diabetic heart disease, aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, inflammatory, membrane stabilizer, belonging to the thyroxine treatment class of molecules, and it has an effect on cancer as well as impacts pancreatitis. The molecule is a energy source and nutrient, and it impacts obesity. The molecule is a energy storage that impacts metabolic syndrom... | CCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C | [
"Fat storage",
"inflammatory",
"Pancreatitis",
"Thyroxine treatment",
"Cancer",
"Membrane stabilizer",
"Energy source",
"nutrient",
"Obesity",
"Metabolic syndrome",
"Cardiovascular disease",
"Energy storage",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, energy storage, inflammatory that impacts metabolic syndrome and lipotoxicity. | CC(C)CCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Metabolic syndrome",
"Membrane stabilizer",
"Energy source",
"Energy storage",
"inflammatory",
"Lipotoxicity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, barth syndrome, and aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Apoptosis",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pesticide and bruchifuge, belonging to the anti retinitic class of molecules, and is anti atherosclerotic. The molecule is a prooxidant and ubiquiot, belonging to both the anti proliferant and anti oxidant classes of molecules, and is anti nyctalopic. Upon decomposition, emits highly toxic fumes of su... | CS | [
"anti retinitic",
"pesticide",
"bruchifuge",
"anti atherosclerotic",
"anti nyctalopic",
"anti proliferant",
"prooxidant",
"ubiquiot",
"anti oxidant",
"Decomposition_evaluation",
"anti radicular",
"retinoprotectant",
"quinone-reductase inducer",
"anti tumor",
"Odor_evaluation",
"taste_e... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is saffron, fruity, floral, and sage. The molecule is a nutrient, clary, tea, and herbal. | CC1=CCC(C)C(C)C12C=CC(C)O2 | [
"saffron",
"fruity",
"floral",
"sage",
"nutrient",
"clary",
"tea",
"herbal"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease, barth syndrome, non-alcoholic fatty liver disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts aging. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti tumor class of molecules. | O=C(O)c1c2c(c3ccc(OCCO)cc3c1C(=O)O)C(=O)c1ccccc1C2=O | [
"anti tumor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a dppiv inhibitor and belongs to the diabetes treatment class of molecules. | Cc1cc2cc(C#N)ccc2n1CC(C)NCC(=O)N1CCCC1C#N | [
"dppiv inhibitor",
"diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the cancer treatment class of molecules. | CC(=Cc1csc(C)n1)C1CC2OC2(C)CC=CC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)O1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts non-alcoholic fatty liver disease and aging. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, tangier disease, and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Diabetic heart disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.